232P Adjuvant therapy for EGFR-mutant non-small cell lung cancer: A network meta-analysis of phase III trials
Conclusions: Our findings suggest that adjuvant EGFR-TKI therapy may confer survival benefits on selected stage IA NSCLC patients harboring EGFR mutations, particularly those with high risk of local recurrence and distant metastasis.Molecular testing and individualized postoperative management should be considered to optimize patient outcomes.
Authors
- Z. Liu
- J. Luo
- Z. Li
Institutions
- Shanghai Jiao Tong University (CN)
- Shanghai Chest Hospital (CN)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106540
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00